○Maimaitijiang Guzailiayi1, Jun-ichi Kira1,2,3, Yuri Nakamura1,2,3, Mitsuru Watanabe4, Ayako Sakoda1,2, Katsuhisa Masaki4, Satoshi Nagata4, Hiroo Yamaguchi4, Ryo Yamasaki4, Noriko Isobe4, Xu Zhang1, Tomohiro Imamura1,3 (1.Translational Neuroscience Center, Graduate School of Medicine, International University of Health and Welfare, Japan, 2.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare, 3.School of Pharmacy at Fukuoka, International University of Health and Welfare, 4.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University)
Session information
Oral Session
[O-06] Oral Session 06
Wed. May 18, 2022 3:35 PM - 5:05 PM Room10 (Tokyo International Forum G Block 4F G409)
Chair:Sachiko Miyake(Department of Immunology, Juntendo University Graduate School of Medicine), Tatsuro Misu(Department of Neurology, Tohoku University Hospital)
○Cossu Davide1,2, Yokoyama Kazumasa1, Sato Shigeto1, Noda Sachiko1, Sakanishi Tamami1, Sechi Leonardo A.2, Hattori Nobutaka1 (1.Juntendo University, Japan, 2.Sassari University, Italy)
○Yuki Matsumoto1, Kunio Tarasawa2, Tatsuro Misu3, Chihiro Namatame1, Yoshiki Takai3, Hiroshi Kuroda4, Kazuo Fujihara5,6, Kiyohide Fushimi7, Kenji Fujimori2, Masashi Aoki1,3 (1.Tohoku University Graduate School of Medicine, Department of Neurology, Japan, 2.Tohoku University Graduate School of Medicine, Department of Health Administration and Policy, Sendai, Japan, 3.Tohoku University Hospital, Department of Neurology, Sendai, Japan., 4.Miyagi South Medical Center, Miyagi, Japan., 5.Fukushima Medical University, Department of Multiple Sclerosis Therapeutics, Fukushima, Japan, 6.Southern Tohoku Research Institute for Neuroscience, Multiple Sclerosis & Neuromyelitis Optica Centre, Fukushima, Japan, 7.Tokyo Medical and Dental University Graduate School of Medicine, Department of Health Policy and Informatics, Tokyo, Japan.)
[O-06-4] Astroglial connexin 43 is a novel therapeutic target for a chronic multiple sclerosis model
○Ozdemir Ezgi1, Yamasaki Ryou1, Nagata Satoshi1, Watanabe Mitsuru1, Yamaguchi Hiroo1, Masaki Katsuhisa1, Kira Jun-ichi2,3, Takeuchi Hideyuki4, Isobe Noriko1 (1.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, 3.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, 4.Department of Neurology and Stroke Medicine, Graduate School of Medicine, Yokohama City University)
○Shohei Beppu1, Makoto Kinoshita1, Wilamowski Jan2, Tadahiro Suenaga3, Tatsusada Okuno1, Standley Daron M.2,4, Hideki Mochizuki1 (1.Department of Neurology, Graduate School of Medicine, Osaka University, Japan, 2.Department of Genome Informatics, Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, 3.Department of Microbiology, Fukushima Medical University, 4.Systems Immunology Laboratory, WPI Immunology Frontier Research Center, Osaka University)
○Mitsuru Watanabe1, Eriko Matsuo1, Shoko Fukumoto1, Eizo Tanaka1, Katsuhisa Masaki1, Takuya Matsushita1, Jun-ichi Kira1,2,3, Noriko Isobe1 (1.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, 3.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, International University of Health and Welfare)